Cinnamon, Chromium & ALA for Blood Sugar: Independent Evidence

Table of contents

• Evidence summary
• What these supplements are, and how they are regulated
• How they are supposed to work
• What works and what does not
• Benefits by claim
• Risks and all side effects
• All interactions
• Who should avoid them
• Doses studied and product quality
• Follow the money: who makes it and who funded the evidence
• Related research
• Frequently asked questions
• Sources and funding notes

Evidence summary

Independent evidence and credibility scorecard

Independence tiers: 1 = regulator or government body; 2 = academic or Cochrane team with no declared commercial funding for the work; 3 = independent authors analysing mostly manufacturer-run trials, or minor declared industry ties; 4 = manufacturer-funded or manufacturer-authored. Credibility runs from A (highest) to D.

Seven of our twelve graded sources are government bodies, and five are American. The safety findings come mostly from European regulators (Germany and the EU), while the benefit claims come mostly from meta-analyses written in Iran, Thailand and China. Where a US government review (NIH ODS on chromium) and a regulator on the other side of the world (FSANZ) both reach unenthusiastic conclusions about chromium, that convergence matters more than any single positive meta-analysis.

What these supplements are, and how they are regulated

Cinnamon is the dried bark of several Cinnamomum trees. "True" or Ceylon cinnamon is C. verum; cassia covers C. cassia, C. loureiroi and C. burmannii. All are sold as "cinnamon" in the US, and a University of Mississippi analysis found that local cinnamon, cinnamon foods and cinnamon supplements were probably Indonesian cassia (Wang 2013). NCCIH notes that trial results are hard to interpret because it is often unclear which species or plant part was tested (NCCIH).

Chromium is an essential trace mineral. Supplements use chromium picolinate, chromium chloride, chromium-enriched yeast and branded forms (Costello 2016). In the EU and UK, foods that are a source of chromium may lawfully say "Chromium contributes to the maintenance of normal blood glucose levels" (Regulation 432/2012, annex). That claim is about normal physiology, not treating diabetes. The FSANZ review notes that the evidence behind a chromium–glucose link in deficiency comes from case reports of intravenous chromium in people on long-term drip feeding (FSANZ 2016).

Alpha-lipoic acid (thioctic acid) is an antioxidant made in the body and sold as a supplement. In Germany it has a long history as a medicine for diabetic nerve damage, and the largest trials were run with a pharmaceutical company (NATHAN 1). The EU reviewed its safety as a food ingredient under Article 8 of the fortified-foods regulation (EFSA 2021).

Bitter melon (Momordica charantia, bitter gourd) is a vegetable widely used in traditional medicine in Asia and Africa. Trials have used juice, dried fruit, capsules and extracts, and the Cochrane team found no preparation was tested twice (Cochrane 2012).

Apple cider vinegar is a dilute acetic acid solution sold as a liquid, tablets or gummies. In the US, all five are sold as dietary supplements or foods without pre-market proof of benefit.

How they are supposed to work

• Cinnamon: polyphenols are proposed to improve insulin signalling. A small 2024 crossover trial of 4 g/day found lower 24-hour glucose and raised levels of the gut hormone GIP after cinnamon (Zelicha 2024). The mechanism in humans is not established.
• Chromium: thought to support insulin action. FSANZ found no established mechanism (FSANZ 2016). True dietary deficiency appears rare outside drip-fed patients.
• Alpha-lipoic acid: an antioxidant; proposed to reduce oxidative nerve damage. Its sulfhydryl chemistry is the suspected link to insulin autoimmune syndrome (EFSA 2021).
• Bitter melon: some components are structurally similar to animal insulin in lab work (Basch 2003). Human proof is lacking.
• Vinegar: slows stomach emptying. In 10 people with type 1 diabetes and gastroparesis, 30 ml of vinegar slowed emptying further (median gastric emptying rate 27% with water vs 17% with vinegar) (Hlebowicz 2007). This blunts the after-meal rise, which is also why it can be a problem for insulin users.

What works and what does not

Benefits by claim

Does cinnamon lower blood sugar?

The cleanest summary is unenthusiastic. The Cochrane review pooled 10 trials of cinnamon tablets or capsules, mainly cassia, at an average of 2 g a day. It called the effect on fasting glucose inconclusive, found no significant difference in HbA1c, and concluded the evidence was insufficient for type 1 or type 2 diabetes (Leach & Kumar 2012). A US meta-analysis the following year pooled 10 trials differently and found fasting glucose 24.59 mg/dL (about 1.4 mmol/L) lower, but again no significant effect on HbA1c (−0.16%, 95% CI −0.39 to 0.02) and very high heterogeneity (Allen 2013). HbA1c reflects average glucose over about three months and is the measure that predicts complications, so a fasting-glucose fall without an HbA1c fall is weak support.

NCCIH summarises a 2019 review of 16 studies (1,098 people) in which cinnamon reduced fasting glucose and insulin resistance in prediabetes and type 2 diabetes, but stresses that doses, durations and participants differed (NCCIH). Its cinnamon page says it is "unclear" whether cinnamon helps diabetes (NCCIH).

One trial drove much of the early excitement. A 2003 study of 60 people in Pakistan reported 18–29% falls in fasting glucose with 1, 3 or 6 g of cinnamon (Khan 2003). In 2025 the American Diabetes Association issued an expression of concern, citing baseline differences between groups that were "inconsistent with proper randomization", zero drop-outs and an inability to reach the authors or obtain raw data (ADA 2025).

The most recent well-designed trial is small. In 18 adults with obesity and prediabetes, 4 g a day of cinnamon for four weeks lowered continuously monitored glucose compared with placebo, with no extra gut symptoms (Zelicha 2024). Its registry lists the University of California, Los Angeles as sponsor (NCT04342624); we could not read the paper's funding statement. It did not measure HbA1c over months.

Does chromium picolinate help diabetes or insulin resistance?

Scientists at the NIH Office of Dietary Supplements reviewed 20 randomised trials in type 2 diabetes. Only 5 of 20 brought fasting glucose to target, 3 of 14 brought HbA1c to 7% or below, and 1 of 14 did both. They concluded there is "little rationale" to recommend chromium for glucose control in established type 2 diabetes (Costello 2016).

Pooled meta-analyses read more positively. A Thai analysis of 25 trials reported HbA1c 0.55 percentage points lower (95% CI −0.88 to −0.22) and suggested effects mainly with chromium picolinate above 200 µg a day (Suksomboon 2014). An Iranian analysis of 28 studies reported HbA1c −0.71% and fasting glucose −19.0 mg/dL, but with heterogeneity of 99.8% for glucose, meaning the trials disagreed wildly (Asbaghi 2020). NCCIH cites a 2022 review of 16 studies (868 people) that suggested improvements in HbA1c and fasting glucose (NCCIH).

For prevention, the independent picture is clearer. A GRADE review for the Australian and New Zealand food regulator found "No effect" with moderate certainty on blood glucose in people with normal glucose or impaired glucose tolerance (FSANZ 2016). The US FDA's 2005 qualified claim says "one small study" suggests chromium picolinate may reduce the risk of insulin resistance, and that the relationship is "highly uncertain" (NutraIngredients report of FDA letter; FDA list, dated 25 August 2005). A qualified claim is a permission to market with caveats, not an endorsement.

Does alpha-lipoic acid lower blood sugar?

Probably not meaningfully. NCCIH reports that a 2019 review of 10 studies (553 people) found ALA no better than placebo for blood sugar, cholesterol or triglycerides (NCCIH). An Iranian meta-analysis of 24 trials in mixed "metabolic diseases" reported lower fasting glucose (SMD −0.54) and HbA1c (SMD −1.22) (Akbari 2018). An SMD expresses the effect in standard-deviation units; −0.5 is a moderate effect on paper, but the trials were small and varied.

Does alpha-lipoic acid help diabetic neuropathy?

This is ALA's strongest use, but still mixed. NCCIH cites one 2022 review (9 studies, 2,062 people) suggesting pain relief, and another (8 studies, 1,500 people) in which only 3 studies showed improvement (NCCIH). The four-year NATHAN 1 trial gave 600 mg a day to 460 people. It did not change its primary composite endpoint (p=0.105), though some secondary neuropathy scores favoured ALA. Serious adverse events were 38.1% on ALA and 28.0% on placebo (Ziegler 2011). Three authors were employees of MEDA Pharma, which makes ALA, and others received MEDA fees or grants (NATHAN 1 disclosures).

Does bitter melon work for diabetes?

The Cochrane review found four trials (479 people) with generally high risk of bias. Bitter melon was no better than placebo, metformin or glibenclamide on reliable glucose measures, and the authors said the evidence "does not warrant" its use for treatment (Ooi 2012). Later meta-analyses are more positive: a Chinese review of 8 trials (423 people) reported HbA1c 0.38 percentage points lower (Zhang 2024), and a South African review of 25 trials reported an HbA1c SMD of −0.57 (Mkhize 2025). Neither declared competing interests. Because preparations differ so much, no product can claim the pooled result. NCCIH says research on bitter melon "hasn't proven" it works (NCCIH).

Does apple cider vinegar lower blood sugar?

Small trials say it might, modestly. A 2025 meta-analysis of 7 trials in type 2 diabetes found fasting glucose 21.9 mg/dL lower and HbA1c 1.53 points lower, though the confidence interval for HbA1c was wide (−2.65 to −0.41) (Arjmandfard 2025). A 2021 analysis of 9 trials found smaller effects, with HbA1c heterogeneity of 91% (Hadi 2021). Both were written by Iranian university teams with no commercial funding declared. The most publicised recent vinegar trial, on weight in Lebanese adolescents and young adults, was retracted in 2025 after its analyses could not be replicated and the data showed patterns "inconsistent with random allocation" (BMJ Nutrition, Prevention & Health).

Risks and all side effects

Put that next to the trials. The Cochrane trials averaged 2 g a day of mostly cassia, and some used up to 6 g (Cochrane). By BfR's arithmetic, those doses sit at or up to about three times the tolerable intake for a 60 kg adult. NCCIH takes a softer line, saying doses below 6 g a day "does not appear to pose a health risk" while warning people with liver disease (NCCIH). We report both. BfR also notes that no liver damage from cinnamon as food had been described in the literature at the time of its FAQ (BfR). One case report describes hepatitis in a 73-year-old woman a week after starting cinnamon supplements alongside a statin (Brancheau 2015).

The relevant gene variant DRB1*04:06 is carried by 5.3–13.2% of people in Japan but only 0.1–1% in Europe, which is why many cases are reported from East Asia (EFSA 2021). NCCIH lists headache, heartburn, nausea and vomiting as the commonest side effects of ALA (NCCIH).

Chromium

NCCIH lists stomach pain and bloating, and "a few reports" of kidney damage, liver damage, muscle problems and skin reactions after large doses (NCCIH). Case reports include chronic kidney failure after over-the-counter chromium picolinate (Wasser 1997) and a woman who took 1,200–2,400 µg a day for weight loss and developed anaemia, liver dysfunction and kidney failure needing dialysis, later recovering (Cerulli 1998). A third case involved a multi-ingredient product that also contained synephrine and guarana (Wani 2006). Case reports cannot prove cause or show how common harm is. In trials, adverse events did not differ from placebo at usual doses (Suksomboon 2014).

Bitter melon

Cochrane found no serious adverse effects in trials, but noted diarrhoea and abdominal pain and incomplete reporting (Ooi 2012). A safety review lists hypoglycaemic coma and convulsions in children, a favism-like reaction, reduced fertility in mice and headaches (Basch 2003).

Apple cider vinegar

• Teeth: erosive tooth wear in a 15-year-old who drank a glass of apple cider vinegar daily for weight loss (Gambon 2012). Lab work shows vinegars dissolve enamel minerals, with up to about 20% mineral loss at some depths (Willershausen 2014).
• Potassium and bone: low potassium, high renin and osteoporosis in a patient who drank large amounts of cider vinegar for years (Lhotta 1998).
• Gullet: throat injury after a vinegar tablet lodged; testing of eight tablet brands found wide variation in acidity and label claims (Hill 2005).
• Stomach emptying: further slowing in type 1 diabetes with gastroparesis (Hlebowicz 2007).

Cinnamon: other effects

At higher doses the most common side effects are allergic skin reactions and digestive upset (NCCIH). NCCIH also warns against the "cinnamon challenge", inhaling dry powder, which can cause serious harm (NCCIH).

All interactions

• Diabetes medicines (all five): additive glucose lowering. NCCIH says combining herbal supplements such as cinnamon with conventional diabetes drugs can cause unwanted side effects (NCCIH); a bitter melon review describes possible additive effects (Basch 2003). Risk is highest with insulin and sulfonylureas.
• Cinnamon with liver-straining medicines: a reported hepatitis case with a statin (Brancheau 2015). NCCIH notes possible interactions with an anticancer medicine and nicotine (NCCIH).
• Cinnamon from several sources: coumarin also comes from cinnamon foods and from some body lotions and oils, so totals add up (BfR).
• ALA with insulin-treated diabetes: insulin autoimmune syndrome can be mistaken for an insulin-dosing problem. EFSA's review is the key source (EFSA 2021).
• Vinegar with potassium-lowering medicines: because heavy vinegar use has been linked to low potassium (Lhotta 1998), combining it with medicines that also lower potassium deserves caution. This is our inference from the case report, not a tested interaction.
• Vinegar with mealtime insulin in gastroparesis: slower emptying can mismatch insulin timing (Hlebowicz 2007).
• Chromium: we could not access the NIH ODS chromium fact sheet that lists drug interactions, so we do not list them here.

Who should avoid them

• People with liver disease: avoid large or long-term amounts of cassia cinnamon (NCCIH).
• Children: a 15 kg child reaches the coumarin limit with about 0.5 g cassia a day (BfR); bitter melon has been linked to hypoglycaemic coma in children (Basch 2003).
• Pregnancy and breastfeeding: we found no independent safety data supporting supplement doses of any of the five. Bitter melon reduced fertility in mice (Basch 2003). Gestational diabetes needs proper care; see our related guide below.
• People with kidney disease: NCCIH says those with or at risk of kidney disease need close monitoring of supplement use; diabetes is the leading cause of kidney disease (NCCIH). Chromium has kidney-injury case reports.
• People of East Asian ancestry using ALA: higher carriage of the main risk gene for ALA-induced insulin autoimmune syndrome (EFSA 2021).
• People with G6PD deficiency: bitter melon has been linked to a favism-like reaction (Basch 2003).
• People with gastroparesis, tooth erosion, reflux or swallowing problems: vinegar drinks and tablets (Hlebowicz 2007; Hill 2005).
• Anyone tempted to stop prescribed treatment: FDA warns that products claiming to replace diabetes medicine are illegal (NCCIH).

Doses studied and product quality

These are doses used in research, not advice.

• Cinnamon: 0.5–6 g a day (mean 2 g) for 4–16 weeks in the Cochrane trials (Cochrane); 120 mg to 6 g a day in Allen's pooling (Allen 2013); 4 g a day in the 2024 prediabetes trial (Zelicha 2024).
• Chromium: trials ranged from 1.28 to 1,000 µg of elemental chromium a day in several chemical forms (Costello 2016).
• Alpha-lipoic acid: 600 mg once daily for four years in NATHAN 1 (Ziegler 2011); insulin autoimmune cases occurred at 200–800 mg a day (EFSA 2021).
• Bitter melon: no preparation was tested twice in the Cochrane trials (Ooi 2012).
• Apple cider vinegar: effects on fasting glucose rose with dose, about 1.26 mg/dL lower per extra mL a day (Arjmandfard 2025); a subgroup took 15 mL a day or less (Hadi 2021).

Product quality problems

• Wrong cinnamon: coumarin was detected in every locally bought cinnamon, cinnamon food and cinnamon supplement tested in one US study, consistent with cassia (Wang 2013). Powdered Ceylon and cassia are almost impossible to tell apart by eye (BfR).
• Lead in cinnamon: in March 2024 the FDA told consumers to discard several ground-cinnamon brands sold through discount and grocery chains after finding lead at about 2–3.4 ppm (FDA alert). In 2023 cinnamon apple-puree pouches were recalled for elevated lead and chromium (FDA investigation).
• Vinegar tablets: eight brands varied widely in size, acidity and acid content, and the authors doubted some contained apple cider vinegar at all (Hill 2005).
• Coumarin limits: the EU caps coumarin in cinnamon foods (50 mg/kg in traditional cinnamon baked goods, 5 mg/kg in desserts) but sets no limit for cinnamon as a spice (BfR). In the US, coumarin is banned as an additive but not regulated when it comes from cinnamon (Wang 2013).

Follow the money: who makes it and who funded the evidence

Who makes and sells it

• Chromium picolinate: Nutrition 21 filed the petition behind the 2005 FDA qualified claim; FDA allowed one claim and declined others the company proposed (NutraIngredients). Chromax is now listed as a registered trademark of "Nutrition21, LLC or American River Nutrition, LLC" and is marketed by Everwell Health of Saddle Brook, New Jersey, whose own owner the site does not state (Everwell Health). The brand describes Chromax as the "most clinically tested" chromium picolinate and claims absorption "up to 15x" better than other forms (Chromax). These are the seller's claims; we found no independent test of them.
• Alpha-lipoic acid: MEDA Pharma GmbH & Co. KG of Bad Homburg, Germany, employed three NATHAN 1 authors (NATHAN 1). ALA is also sold by many generic supplement makers.
• Cinnamon: mostly cassia; US products tested were probably Indonesian C. burmannii (Wang 2013). Cinnamon is a commodity spice; no single company dominates the supplement market that we could document.
• Bitter melon and apple cider vinegar: sold by many small brands; we found no dominant owner to trace.

Who funded the trials

• Cochrane reviews: cinnamon authors declared no known interests (Cochrane cinnamon); the bitter melon review authors, at Universiti Putra Malaysia, also declared "None known" (Cochrane bitter melon).
• Chromium: the most sceptical review came from NIH Office of Dietary Supplements staff with partial USDA support (Costello 2016). It was published in Nutrition Reviews, which Oxford University Press issues on behalf of the International Life Sciences Institute, a body funded largely by food companies (journal footer on the same record). The positive pooled analyses came from Thai and Iranian universities; we could not see their funding statements.
• ALA: the largest long-term trial was co-authored by the manufacturer's staff, and several academic authors received MEDA fees, grants or royalties (NATHAN 1).
• Vinegar: both main meta-analyses were Iranian, one supported by a university student research committee and one with no funding (Arjmandfard 2025; Hadi 2021).
• Cinnamon trials: the 2024 prediabetes trial lists UCLA as sponsor (NCT04342624); we could not read its funding statement.

Documented integrity events

• 2025: American Diabetes Association expression of concern on the 2003 Khan cinnamon trial (Diabetes Care).
• 2025: retraction of the 2024 apple cider vinegar weight-loss trial; the authors attributed discrepancies to honest mistakes but agreed to retract (BMJ NPH).
• 2024: FDA alert and recalls of ground cinnamon contaminated with lead (FDA).
• 2023: recall of cinnamon apple pouches over lead and chromium (FDA).
• 2021: EFSA's finding that ALA in foods is likely to raise insulin autoimmune syndrome risk (EFSA).

Related research

For wider, evidence-graded context, see these Pure City Research guides:

• Berberine: glucose evidence, formulations and safety
• Diabetes supplements: benefits, limits and safety
• Type 2 diabetes: prevention and management evidence
• Diabetes and heart disease
• Psyllium husk: cholesterol, blood sugar and safety
• Myo-inositol: PCOS, pregnancy trials and safety
• Drug and supplement induced liver injury
• Atorvastatin: uses, side effects and interactions
• Monk fruit: blood sugar evidence and safety

Frequently asked questions

Sources and funding notes

What we could not verify: the NIH Office of Dietary Supplements chromium fact sheet (blocked to our requests), so chromium intake values and drug interactions are not given; the full FDA 2005 letter (the archived copy timed out; we relied on FDA's list and a trade-press report quoting it); the full EFSA 2010 chromium claims opinion (we used the EU authorised-claims list instead); the full EFSA 2008 coumarin opinion (we relied on BfR's statement that EFSA set the same limit); the funding statements of the Suksomboon, Asbaghi, Akbari and Zelicha papers and of the Wang coumarin study; the ADA Standards of Care text on supplements (blocked); whether the EU has since restricted ALA in foods following EFSA's opinion; the full text of the 2012 Cochrane cinnamon review (blocked to our requests), so we give its conclusions but not its pooled effect sizes or its trial-by-trial bias ratings; the sources-of-support section of the Cochrane bitter melon review; the current corporate owner of Nutrition21, LLC and of Everwell Health; and the current owner of MEDA's ALA products. We found no market-size data from a citable independent source.

1. NCCIH: Diabetes and Dietary Supplements: What You Need To Know (last updated November 2023) — US government; funded by Congress (appropriations history).
2. NCCIH: Cinnamon (November 2024) — US government.
3. BfR: FAQ on coumarin in cinnamon and other foods (updated from 27 September 2012) — German federal risk assessor.
4. EFSA NDA Panel: Scientific opinion on alpha-lipoic acid and the risk of insulin autoimmune syndrome (2021) — EU agency.
5. Chu A, Samman S. Systematic review of chromium and glycaemic control, for FSANZ (2016) — University of Otago for the Australia–New Zealand food regulator.
6. FDA: Qualified Health Claims: Letters of Enforcement Discretion — lists the chromium picolinate claim, 25 August 2005; US regulator.
7. NutraIngredients: Qualified health claim for chromium picolinate cleared by FDA (29 August 2005) — trade press, advertising-funded; used only for the quoted FDA wording.
8. Regulation (EU) No 432/2012, Annex (authorised health claims) — EU law as retained in the UK.
9. Leach MJ, Kumar S. Cinnamon for diabetes mellitus. Cochrane 2012 (full text) — Australian academic authors; declarations "None known".
10. Allen RW et al. Cinnamon use in type 2 diabetes. Ann Fam Med 2013 — US academic; no conflicts; no funder named.
11. Khan A et al. Cinnamon improves glucose and lipids. Diabetes Care 2003 — Pakistani trial; subject of expression of concern.
12. American Diabetes Association. Expression of concern. Diabetes Care 2025 — journal publisher.
13. Zelicha H et al. Cinnamon spice and continuously monitored glucose in prediabetes. Am J Clin Nutr 2024 — UCLA; registry NCT04342624; funding statement not accessed.
14. Costello RB, Dwyer JT, Bailey RL. Chromium supplements for glycemic control. Nutr Rev 2016 (full text) — NIH ODS; partial USDA support.
15. Suksomboon N et al. Chromium supplementation in diabetes. J Clin Pharm Ther 2014 — Mahidol University, Thailand; funding not accessed.
16. Asbaghi O et al. Chromium and glycemic control. Pharmacol Res 2020 — Iranian universities; funding not accessed.
17. Akbari M et al. Alpha-lipoic acid and glucose control. Metabolism 2018 — Iranian and Canadian universities; funding not accessed.
18. Ziegler D et al. NATHAN 1 trial. Diabetes Care 2011 (full text and disclosures) — MEDA Pharma employees among authors.
19. Ooi CP et al. Momordica charantia for type 2 diabetes. Cochrane 2012 — Universiti Putra Malaysia; declarations "None known"; support statement not seen.
20. Zhang X et al. Momordica charantia and glycaemic control. Heliyon 2024 — Henan University of Chinese Medicine; no competing interests declared.
21. Mkhize SAL et al. Momordica charantia in prediabetes and type 2 diabetes. Metabol Open 2025 — South African universities; no specific grant.
22. Basch E et al. Bitter melon: efficacy and safety. Am J Health Syst Pharm 2003 — Natural Standard (commercial evidence database).
23. Arjmandfard D et al. Apple cider vinegar and glycemic control. Front Nutr 2025 — Shiraz University of Medical Sciences student research committee; no conflicts.
24. Hadi A et al. Apple cider vinegar, lipids and glycemic parameters. BMC Complement Med Ther 2021 — Iranian and UK authors; no funding.
25. Retraction: Apple cider vinegar for weight management in Lebanese adolescents and young adults. BMJ Nutr Prev Health 2025 — journal notice; original PMID 38966098.
26. Lhotta K et al. Hypokalemia, hyperreninemia and osteoporosis with cider vinegar. Nephron 1998 — Innsbruck University Hospital case report.
27. Hill LL et al. Esophageal injury by apple cider vinegar tablets. J Am Diet Assoc 2005 — University of Arkansas.
28. Gambon DL et al. Erosion by apple cider vinegar. Ned Tijdschr Tandheelkd 2012 — Dutch case report.
29. Willershausen I et al. Dental erosion by vinegar varieties in vitro. Clin Lab 2014 — German laboratory study.
30. Hlebowicz J et al. Apple cider vinegar and gastric emptying in type 1 diabetes. BMC Gastroenterol 2007 — Lund University, Sweden.
31. Brancheau D et al. Do cinnamon supplements cause acute hepatitis? Am J Case Rep 2015 — US hospital case report; no conflicts.
32. Wasser WG et al. Chronic renal failure after chromium picolinate. Ann Intern Med 1997; Cerulli J et al. Chromium picolinate toxicity. Ann Pharmacother 1998; Wani S et al. Acute tubular necrosis. Ann Pharmacother 2006 — US case reports.
33. Wang YH et al. Cassia cinnamon as a source of coumarin in US foods and supplements. J Agric Food Chem 2013 — University of Mississippi; funding not accessed.
34. FDA alert: cinnamon products with elevated lead (6 March 2024) — US regulator.
35. FDA investigation: lead and chromium in cinnamon applesauce pouches (2023) — US regulator.
36. Everwell Health: About us and Chromax product page — seller's own pages; marketing claims.
37. Cochrane commercial sponsorship policy — Cochrane.

Educational research reviewed 9 October 2026. This article is not medical advice; talk to a qualified clinician or pharmacist before starting, stopping or combining treatments.